Showing 2171-2180 of 2527 results for "".
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- Study Points to Potential New Approach to Treating Glaucoma and Alzheimer’s Diseasehttps://modernod.com/news/study-points-to-potential-new-approach-to-treating-glaucoma-and-alzheimers-disease/2478060/Researchers at Vanderbilt University Medical Center (VUMC) have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy. In doing so, however, the undamaged optic nerve becomes vu
- Glaucoma Study Findings Emphasize Need for Regular Eye Checkshttps://modernod.com/news/glaucoma-study-findings-emphasize-need-for-regular-eye-checks/2478048/People with early-stage glaucoma see the contrast of visible objects in a very similar way to people without the condition, a new study has shown. Research by the University of Bradford (UK) demonstrated that the brain compensates for the changes in the eye caused by glaucoma, when looking
- Oxford-AstraZeneca Covid Vaccine Study Shows Dual Immune Actionhttps://modernod.com/news/oxford-astrazeneca-covid-vaccine-study-shows-dual-immune-action/2478042/A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen, according to a Bloomberg
- UK, US, Canada Accuse Russia of Hacking Virus Vaccine Trialshttps://modernod.com/news/uk-us-canada-accuse-russia-of-hacking-virus-vaccine-trials/2478034/Britain, the United States and Canada accused Russian hackers on Thursday of trying to steal information from researchers seeking a coronavirus vaccine, warning scientists and pharmaceutical companies to be alert for suspicious activity, according
- A Potential New Approach to Combat Drug Resistance in Age-Related Macular Degenerationhttps://modernod.com/news/a-potential-new-approach-to-combat-drug-resistance-in-age-related-macular-degeneration/2478031/An international team of researchers led by Baylor College of Medicine and Houston Methodist has discovered a strategy that can potentially address a major challenge to the current treatment for choroidal neovascularization (CNV), according to a university news release. Anti-vascular endot
- Novartis to Provide 15 Drugs at Zero-Profit for Treating COVID-19 Symptomshttps://modernod.com/news/novartis-to-provide-15-drugs-at-zero-profit-for-treating-covid-19-symptoms/2478027/Novartis announced Thursday that 15 generic and over-the-counter medicines from its Sandoz unit will be made available at zero-profit to treat the major symptoms of COVID-19 in low-income and lower-middle-income countries. The drugs include those to treat gastro-intestinal illness, acute respirat
- Reports Hint at Positive Data Coming for AstraZeneca, Oxford Coronavirus Vaccinehttps://modernod.com/news/reports-hint-at-positive-data-coming-for-astrazeneca-oxford-coronavirus-vaccine/2478028/Reports emerged that positive news will be released soon on AstraZeneca’s experimental COVID-19 vaccine that it is working on with the University of Oxford. The Lancet has also confirmed that data from a phase 1 trial of AZD1222, formerly known as ChAdOx1 nCoV-19, will be published
- AstraZeneca, IQVIA Partner to Speed Up Studies of COVID-19 Vaccine Candidatehttps://modernod.com/news/astrazeneca-iqvia-partner-to-speed-up-studies-of-covid-19-vaccine-candidate/2478022/AstraZeneca and IQVIA are teaming up to accelerate development of the UK drugmaker’s Oxford University-partnered COVID-19 vaccine candidate AZD1222, IQVIA announced Tuesday. According to the life sciences data analytics firm, the collaboration will “drive faster delivery of clin